key: cord-0892187-2bpggqrw
authors: Khamis, Amar Hassan; Jaber, Mohamed; Azar, Aida; AlQahtani, Feras; Bishawi, Khaled; Shanably, Ahmed
title: Clinical and laboratory findings of COVID-19: A systematic review and meta-analysis
date: 2020-12-15
journal: J Formos Med Assoc
DOI: 10.1016/j.jfma.2020.12.003
sha: 4294282c688fa307e9cb829ac077112fcf84e9db
doc_id: 892187
cord_uid: 2bpggqrw

BACKGROUND/PURPOSE: The aim of this study was to systematically review all COVID-19 publications to summarize the clinical features, assess comorbidities, prevalence, and disease outcomes. METHODS: Included were all COVID-19 published studies between January 1 to July 20, 2020. The random effect model was used to calculate the pooled prevalence and corresponding 95% confidence interval (CI). Publication bias was assessed using the funnel plot for the standard error by logit event. RESULTS: The mean age of the patients was 46.8 years (95% CI, 41.0–52.6) and males comprised 54.0% (95% CI, 51.3–56.7). Total co-morbidities prevalence was 29.5% (95% CI, 19.0–36.6), with diabetes mellitus being the most prevalent 13.8% (95% CI, 8.7–21.1), followed by hypertension 11.7% (95% CI, 5.7–22.6), and cardiovascular disease 9.7% (95% CI, 6.5–14.2). The most common clinical manifestations were fever, 82.0% (95% CI, 67.7–90.8), cough 54.3% (95% CI, 45.5–62.9), fatigue 30.2% (95% CI, 23.3–38.1), sputum 28.5% (95% CI, 21.2–37.2), sore throat 21.7% (95% CI, 14.6–31.0), and headache 11.0% (95% CI, 7.9–15.2). The most common COVID-19 serious complications were RNA Anemia 98.2% (95% CI, 96.2–99.2), hospitalization 83.7% (95% CI, 76.0–89.3), bilateral pneumonia 70.9% (95% CI, 58.2–81.0); of those hospitalized 43.5% (95% CI, 24.9–64.2) were discharged. Fatality accounted for 10.5% (95% CI 6.8–16.1). CONCLUSION: Patients infected with COVID-19 coronavirus showed a wide range of clinical presentation with non-specific symptoms.

The common human coronaviruses are usually harmless viruses causing mild illnesses, such as the common cold. 1 However, certain types of coronaviruses infect the lower respiratory airways, and are causing pneumonia and bronchitis. 2 Coronaviruses structure, as seen under an electron microscope, have large single-stranded RNA genomes at its center, surrounded by a spherical fatty outer layer, with a crown or "corona" of club-shaped spikes on its surface. 2 The new coronavirus, SARS-CoV-2, which causes COVID-19 appears to have first emerged in Wuhan, China, in late 2019. The outbreak has since spread across China to other countries around the world. By the end of January 2020, the World Health Organization (WHO) declared the new coronavirus a public health emergency of international concern. 3 Reported COVID-19 symptoms range from mild to severe. The most common symptoms include fever, dry cough, tiredness, runny nose, and sore throat. 4 Severe COVID-19 cases may develop difficulty breathing, organ failure, and consequently requiring critical care respiratory ventilation with specialized management at intensive care units (ICU), and the most severe complication death. 3,5e10 Similarities in the epidemiology, clinical features, and management have been reported in SARS, MERS, and COVID-19 coronaviruses. 5,7,11e13 These coronaviruses are enveloped by a positive-stranded RNA isolated from bats sharing sequence homology with isolates from humans, suggesting bats as the natural host and reservoir. 11, 12, 14 Differences in these coronaviruses have been noted in their clinical picture. Cough frequency was reported highest in SARS (92.1%), 15 than in MERS (72%) patients, 16 and COVID-19 (57.6%). 14 On the other hand, diarrhea was reported in 20e25% of SARS and MERS patients, and as low as 7% in COVID-19 patients. 7, 9, 12, 17 The case-fatality rate (3.5%) of COVID-19 has been reported to be much lower than that of SARS (9.6%) and MERS (34.4%). 18 Several studies on the emergence of COVID-19 have been published in China and other countries. 8,19e21 Studies have reported clinical findings, evolution, outcome of the disease, potential risk factors, laboratory and image findings. However, the literature still lacks systematic review that consolidates clinical and laboratory findings. The aim of this systematic review and meta-analysis is to summarize the currently available clinical features of COVID-19 and to examine the outcome of its cases.

The protocol was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P), the reporting used the PRISMA checklist and registered with PROSPERO register (registration number CRD42020199625).

The databases PubMed, EMBASE, Cochrane, Scopus, and Google scholars were reviewed from January 1 to July 20, 2020, to identify relevant COVID-19 English language published studies. The Medical Subject Headings (MeSH) terms selected included" Novel coronavirus 2019", "2019 nCoV", "COVID-19", "Wuhan coronavirus," Wuhan pneumonia," and "SARS-CoV-2." The search strategy used the PICO framework: P (Population, children and adult patients with COVID-19), I (Intervention or exposure for observational studies, exposure to SARS-CoV), C (Comparison, recovered and non-recovered cases), and O (Outcome, cure rate).

Included in the analysis were published peer-reviewed articles from January 1 to July 20, 2020, that reported cases of confirmed SARS-CoV-2. Excluded from the analysis were studies reporting COVID-19 cases with incomplete information.

The following was retrieved from each published article: name of authors, date of publication, study location, aims and objectives, source of participants, number of patients, study design, population demographic data (gender and age), eligibility criteria, comorbidities, measurement of exposure and outcome; clinical, laboratory findings, CT imaging features, and follow-up data, and treatment outcomes.

The recommended Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist, 22 was used to assess the risk of bias in all identified full-text articles. The quality of the included studies was assessed independently by two authors (FQ, KB). Twelve checklist criteria were selected and articles were classified into one of three categories of bias: (1) low-risk, where 9 out of 12 criteria were selected, (2) moderate risk, 6 to 8 criteria were selected, and (3) high-risk, only 5 criteria were selected (Table 1) .

Meta-Analysis was used to analyse the data using the comprehensive Meta-Analysis (CMA) package, version 3. Percentages were calculated to describe the distribution of the categorical dichotomous variables. For continuous data, the mean and 95% confidence intervals (CI) were calculated. Studies reporting the mean with 95% CI, the formula (upper limit-lower limit)/4 was used to extract the standard deviation.

Meta-Analysis using the random-effect model was performed to estimate the pooled prevalence and 95% CI. Pooled percentage, prevalence, and corresponding 95% CI were calculated to summarize the weighted effect size for all binary variables. The measure of heterogeneity reported included the Cochran's Q statistics, I 2 index with the level of heterogeneity defined as poor< 25, moderate >50, and high> 75, and the tau square (T 2 ) test. Publication bias was assessed with a funnel plot and the Egger test. Figure 1 shows the literature retrieval flowchart. Five databases (PubMed, EMBASE, Cochrane database, Scopus, and Google Scholar) were searched from January 1 to July 20, 2020. One-hundred and eighteen studies were identified using the predefined search strategy and manual search. Eight duplicate studies were excluded and 71 did not meet the eligibility criteria, such as meta-analysis, review, or mechanism of COVID-19 infection. For this reason, fortyone studies were selected for full-text review. After revision, 6 studies were excluded due to lack of information, comment, or viewpoint.

The final analysis included 35 studies published between January 1 to July 20, 2020. Following the checklist criteria, all 35 screened articles were ranked as low risk of bias, with a weighted kappa statistic between author agreements of 11 2/06/2020 China Cross-Sectional 29 11 Wang et al. 25 2/07/2020 China Cross-Sectional 138 9 Kui et al. 26 2/07/2020 China Cross-Sectional 137 11 Chang et al. 27 2/07/2020 China Cross-Sectional 13 9 To et al. 28 2/12/2020 China Cross-Sectional 12 10 COVID-19 team 29 2/12/2020 Australia Cross-Sectional 15 11 Yueying et al. 30 2/13/2020 China Cross-Sectional 63 9 Li et al. 31 2/13/2020 China Case-Series 24 11 Feng et al. 32 2/13/2020 China Case-Series 21 9 Liang et al. 33 2/14/2020 China Cross-Sectional 1590 10 Zhang et al. 34 2/15/2020 China Case-Series 9 10 Feng et al. 35 2/17/2020 China Case-Series 15 11 Wang et al. 17 2/17/2020 China Cross-Sectional 34 9 Xiaobo et al. 36 2/21/2020 China Cross-Sectional 52 10 Zhou 37 28/3/2020 China Cohort, Retrospective 191 11 Qiu H. 38 25/3/2020 China Cohort, Prospective 36 11 Wang et al. 39 12/3/2020 China Case-Study 1 9 Xia 40 5/03/2020 China Cohort, Retrospective 20 9 Wan et al. 41 21/3/2020 China Cohort, Retrospective 135 10 Liu et a. 42 27/3/2020 China Cohort, Retrospective 56 10 Zhao 43 12/3/2020 China Cohort, Retrospective 19 10 Zhou et al. 10 05/3/2020 China Cohort, Retrospective 62 11 Wang 44 16/3/2020 China Cohort, Retrospective 69 10 Lei et al. 45 5/4/2020 China Cross-Sectional 20 10 Lei Pan et al. 46 14/4/2020 China Cross-Sectional 204 9 Fan et al. 47 21/4/2020 China Cross-Sectional 150 10 Richardson et al. 48 22/4/2020 USA Case Series 5700 10 Li et al. 49 15/5/2020 China Cohort, Retrospective 93 9 Hong et al. 50 7/4/2020 South Korea Cohort, Retrospective 98 11 Garazzino et al. 51 7/5/2020 Italy Cross-Sectional 168 10 Zacharia et al. 52 3/6/2020 USA Case series 50 9 Matos et al. 53 26/6/2020 Italy Cross-Sectional 106 11 Li et al. 54 11/6/2020 China Cohort, Retrospective 102 10 Alsofayan et al. 55 31/5/2020 KSA Cross-Sectional 1519 11

Clinical Findings of COVID-19

87%. The study designs were either cross-sectional or cohort (Table 1) . Twenty-nine variables were included in the Meta-Analysis (Tables 2e5). Most of the studies showed considerable heterogeneity (I 2 >75%) ( Table 6 ). No evidence of bias as demonstrated by Egger's test (P-value > 0.05) ( Table 6 ).

The total number of patients analyzed was 10,972. The mean age of the patients across the studies was 46.8 years (95% CI, 41.0e52.6) and males comprised 54% (95% CI, 51.3e56.7) of the population (Table 6 ).

The total prevalence of co-morbidities in the 17 included studies was 29.5% (95% CI, 19.0e36.6), the most prevalent being diabetes mellitus (DM) 13.8% (95% CI, 8.7e21.1), hypertension 11.7% (95% CI, 5.7e22.6), cardiovascular disease (CVD) 9.7% (95% CI, 6.5e14.2), and chronic obstructive pulmonary disease (COPD) 3.9% (95% CI, 2.9e5.3) ( Table 6 ).

The clinical manifestations of patients diagnosed with COVID-19 included fever, 82.0% (95% CI, 67.7e90.8), cough 54.3% (95% CI, 45.5e62.9), fatigue 30.2% (95% CI, (Table 6 ).

In this study, we analyzed the clinical characteristics of 10,972 confirmed cases infected with novel coronavirus (2019-nCoV) using systematic review and random-effects meta-analysis. The mean age in this study was similar to other published studies that showed that 2019-nCoV mainly infects middle-aged and elderly. 7,56,57 Similar trends were reported for SARS patients where the median age was 52 (25, 78) years and age (per 1-year increase) was reported as a risk factor for death. 58 Another study showed that the median age of MERS non-survivors was 62 (53, 73) which is older than the survivors of the disease 46 (35, 57) years. 16 One of the possible reasons for this phenomenon is that lung aging is associated with an inability of lung cells to multiply resulting in structural and functional changes in the respiratory tract, giving rise to decreased lung function, altered pulmonary remodeling, diminished regeneration, and enhanced susceptibility to pulmonary disease. 59 It is also reported that the older patients have a higher risk of acute respiratory distress syndrome (ARDS) development. 60 This beta coronavirus has been reported to cause ARDS and can be transmitted between humans. 5 It is speculated to use the angiotensinconverting enzyme (ACE) 2 as a receptor for cell invasion. 41 For this reason, some of the 2019-nCoV patients showed rapid progression of lung lesions, which might have led to death.

In the current study, 29.5% of the patients presented with comorbidities, such as CVD (9.7%), hypertension (11.7%), DM (13.8%), and COPD (3.9%). The comorbidities, particularly the CVD and COPD, were considered by some authorities to predict the in-hospital mortality in critically ill patients. 61 It is thought that diabetes may increase the risk of infection and can delay the recovery of the infectious illnesses. In this study, only, 13.8% of patients were In this study, the clinical manifestations of patients diagnosed with COVID-19 infection most commonly includes fever (82.0%) and cough (54.3%). Other studies also reported that fever is the most observed symptom among the effected patients, furthermore, fever frequency is similar in SARS and MERS. 64e67 However, cough frequency was highest in SARS (92.1%), 15 followed by MERS MERS (72%), 16 and least in this COVID-19 study [54.3%] . Other clinical manifestations such as fatigue (30.2%), sputum (28.5%), sore throat (21.7%), headache (11.0%), and hemoptysis (5.3%) were also reported in this study. Similar observations have also been reported by other investigators, 68, 69 nevertheless, these clinical symptoms are rather nonspecific and may mimic influenza or atypical pneumonia of other causes such as mycoplasma, chlamydia, and legionella.

In this study, results of blood investigations showed lymphopenia (41.9%), CRP (48.1%), elevated ESR (23.5%), leukopenia (16.0%), leukocytosis (7.5%), and high creatinine (7.7%). The increased white blood cell (WBC) count 73 Lower lymphocytes counts may be because the viral infection causes persistent consumption and/or insufficient regeneration of lymphocytes. Similar to previous study, the level of CRP in patients infected with 2019-nCoV is high. 5 Moreover, CRP was a significant predictor for disease severity in SARS. 74 In this study, RNA anemia (98.2%) was the most dominant complication of patients infected with COVID-19, followed by patients requiring hospitalization (83.7%), and bilateral pneumonia (70.9%). Furthermore, other studies reported that 45% of patients showed signs of pulmonary fibrosis within one month after being infected with SARS-CoV. 75 Another study found lung fibrosis in 33% of patients who have recovered from MERS-CoV. 76 It is possible that pulmonary fibrosis will become one of the serious complications in patients with 2019-nCoV infection. 77 In this study 10.5% of patients died and similar numbers were recovered and discharged from the hospital. In comparison with data from other countries, for example, in South Korea the case fatality rate (10.4%) was in patients aged 80 years and over, in the 70 year-age group (5.4%), in the 60e69 years (1.51%), in the 50 year age-group (0.37%). Even lower rates were seen in the younger population, dropping to zero in those 29 years and younger, 78 likewise, in China, the case fatality rate was higher in the early 

This research did not receive any specific grant from funding agencies in the public, commercial, or not-forprofit sectors.

Approval was not required.

The authors have no conflicts of interest relevant to this article. 

Viruses and bacteria in the etiology of the common cold

Morphogenesis of coronavirus HCoV-NL63 in cell culture: a transmission electron microscopic study

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Novel coronavirus (2019-nCoV) -situation report -10 30

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The first 2019 novel coronavirus case in Nepal

Emerging understandings of 2019-nCoV

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin

Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia

Travel implications of emerging coronaviruses: SARS and MERS-CoV

History is repeating itself, a probable zoonotic spillover as a cause of an epidemic: the case of 2019 novel Coronavirus

The severe acute respiratory syndrome

Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study

Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen

Zoonotic origins of human coronaviruses

Journey of a Thai taxi driver and novel coronavirus

First case of 2019 novel coronavirus in the United States

First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia

The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

CT imaging features of 2019 novel coronavirus (2019-nCoV)

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan

Consistent detection of 2019 novel coronavirus in saliva

Covid-19 National Incident Room Surveillance Team. COVID-19, Australia: epidemiology report 2

Imaging changes in patients with 2019-nCov

Early transmission dynamics in wuhan, China, of novel coronavirusinfected pneumonia

Analysis of CT features of 15 Children with 2019 novel coronavirus infection

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing

CT image characteristics analysis of 15 cases of children with new coronavirus infection

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

A case report of neonatal COVID-19 infection in China

Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults

Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS

Detection of Covid-19 in children in early

A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias

Clinical features of 69 cases with coronavirus disease 2019 in wuhan

A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study

Imaging characteristics of initial chest computed tomography and clinical manifestations of patients with COVID-19 pneumonia

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area

Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan

Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10

Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in

Evaluation of novel coronavirus disease (COVID-19) using quantitative lung CT and clinical data: prediction of short-term outcome

Predictors of fatality including radiographic findings in adults with COVID-19

Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome

Aging and lung disease

Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome

The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients

Identifying associations between diabetes and acute respiratory distress syndrome in patients with acute hypoxemic respiratory failure: an analysis of the LUNG SAFE database

The effect of diabetes on the risk and mortality of acute lung injury/acute respiratory distress syndrome: a meta-analysis

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

SARS and other coronaviruses as causes of pneumonia

Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group

Coronavirus infections-more than just the common cold

Defining the epidemiology of covid-19 -studies needed

Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis

Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome

Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome

T cell-mediated immune response to respiratory coronaviruses

Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases

Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection

The updates on COVID-19 in Korea as of 24

Global COVID-19 case fatality rates-CEBM. Oxford COVID-19 Evidence Service